People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about … Read more
Eli Lilly said Sunday that new data on Zepbound show the GIP/GLP-1 dual agonist is a better weight loss drug than Novo Nordisk’s Wegovy. Almost 65% of obese or overweight people treated with Zepbound in …
This paper describes a phase 3b clinical trial comparing tirzepatide and semaglutide for weight management in adults with obesity but without diabetes. The SURMOUNT-5 trial randomly assigned participants to receive either tirzepatide or semaglutide weekly for 72 weeks. Tirzepatide was found to be superior to semaglutide in achieving greater reductions in both body weight and waist circumference. While both medications led to similar rates of overall adverse events, predominantly gastrointestinal, tirzepatide resulted … Read more
Ozempic’s double-sided coin: Amid skyrocketing popularity of GLP-1 drugs, a burgeoning lawsuit looms Pittsburgh Post-Gazette Eli Lilly Sues 4 Telehealth Cos. For Weight Loss Drug Copies Law360 Big Pharma Is Winning the Price War Over Weight Loss Drugs Like Ozempic: Will RFK Jr. and His MAHA Allies Push Back? The New York Sun Navigating The GLP-1 Litigation Landscape Life … Read more
TWO blockbuster weight loss just have been tested against each other for the first time in a head-to-head trial. There was a clear winner, which saw slimmers shed 20 per cent of their body weight. AlamyMounjaro helped users lose up to 20 per cent of their body weight[/caption] AlamyMeanwhile, Wegovy saw people lose 13 per … Read more
New research suggests GLP-1 drugs like Ozempic, Wegovy, Mounjaro may lower the risk of several obesity-related cancers, even matching surgery in preventive benefits
In adults with obesity but not diabetes, tirzepatide leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. Medscape Medical News
A MUM has shared a downside of her epic weight loss transformation after being on Mounjaro for over two months. Scottish mum Kirsty took to TikTok after she shed almost a staggering 5 stone while on Mounjaro in a mere nine weeks. One Scottish mum took to TikTok to share the not so desirable side … Read more
INDIANAPOLIS, May 11, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1…
Recent research suggests that Ozempic and other GLP-1 receptor agonists, commonly used for weight loss, may offer unexpected anti-cancer benefits, particularly for obesity-related cancers. Studies indicate these medications could lower cancer risk independently of weight reduction, potentially by reducing inflammation and enhancing immune function. Further research is needed to fully understand their anti-cancer potential.